My interest in natural healing products and medicinal plants such as Cannabis stem from my childhood in Trinidad where I observed my maternal grandmother, a shaman, use herbal medicine to treat me, my five brothers and sister.

As I became more involved in my research, I came to the evolutionary realization that in order to improve health and deal with diseases of the Central Nervous System (CNS) and aging, we have to look to nature.

We are truly an ESG green biotech company dedicated to improving human health and treating chronic diseases in an environmentally-sustainable manner, positively impacting healthcare, climate control and society at large.

• Collaboration with Rhodes Pharma to nanoencapsulate Δ9-THC in biodegradable polymer nanospheres & phospholipid nanosomes
• Collaboration with Alexza Pharmaceuticals to manufacture Δ9-THCA
• Collaboration with Prosulus Pharma to manufacture transdermal patches of Δ9-THC and CBD
• Licensed Seventeen Patents including recent US Patent No. 12,071,419 for Thermal Conversion of CBDA and Other Carboxlylic Cannabinoids
• Grant for Nanoencapsulated CBD for Opioid Use Disorder, NIDA, NIH;
• Grant for Nanoencapsulated Δ9-THC for Marijuana Addiction, NIDA, NIH
• Grant for Development of cGMP Manufacturing Process for CBD from Cannabis sativa, NIDA, NIH; and
• Grant for Development of a Δ9-THC, A Natural Cannabinoid Product, NCI, NIH

Millions of us suffer from addiction, pain, anxiety and Central Nervous System (CNS) disorders such as Multiple sclerosis (MS) and epilepsy.

Addiction: As humans, we can become addicted to many stimulants. Opioid addiction is one of the most intransigent and pervasive addictions. Nearly 645,000 Americans overdosed from opioids from 1999-2021, and just over 100,000 died of drug overdoses in 2022 alone. The US is currently experiencing an opioid epidemic, referred to as an epidemic in the midst of a pandemic, exacerbated by the increased risk of overuse as a result of social and economic stress and disruptions in accessing medical treatments.

Pain: More than 50% of cancer patients suffer from chemotherapy induced peripheral neuropathic pain (CIPNP) for which there are no effective solutions except opioids that have a host of poor side-effects and an addiction potential. CIPNP affects up to 80% of patients during chemotherapy and can limit both dose and choice of therapy. Pain is also endemic with MS, age, and injuries.

Anxiety: Anxiety is an evolutionary response developed by humankind to protect us from physical and mental harm, and is associated with our inherent or natural endocannabinoid system that is connected to our central and peripheral nervous systems. These responses are categorized as generalized anxiety, panic, social-anxiety, obsessive-compulsive, post-traumatic stress and various phobia-related disorders. Generalized Anxiety Disorder (GAD) affects over 15% of US, around 38 million people.

Multiple Sclerosis (MS): MS, a demyelinating and neurodegenerative disease of the central nervous system, remains the primary cause of irreversible, progressive neurologic disability in 2.5 million people worldwide, 1 million of whom are in the US, with 500,000 in the EU. The direct healthcare costs associated with MS are substantial, estimated to be $85.4 billion per year in the US.

Epilepsy: Epilepsy is the 4th most common neurological problem – after migraine, stroke and Alzheimer’s disease. The number of adults over 18 with epilepsy in the US is about 3 million, and approximately 450,000 children aged 17 years and younger have active epilepsy.

We, as humans, have an inherent endocannabinoid or internal cannabinoid system. Unbalances in our internal endocannabinoid system caused by internal and/or external infractions can create unbalances in our health and our abilities to respond to negative health intrusions. Cannabinoids can help rebalance our endocannabinoid system and health.

Cannabinoids can help with anxiety, pain, addiction and other nervous system disorders but we need to keep them in the body longer and protect them from degradation. We do so by encapsulating cannabinoids in nanoparticles made up of biodegradable polymers. As the biodegradable polymers break down in the bloodstream, they release the cannabinoids in a controlled manner. This sustained release of the cannabinoids increases bioavailability, reduces dosing, and improves compliance and efficacy.

Aphios Phama’s projected outcome for Opioid Use Disorder (OUD) by an independent valuation company Xplico ApS, Denmark is shown below:

Aphios Pharma LLC’s business model is to follow one or more of three strategic options:

1. Plan A - Establish a strategic corporate partnership or M&A with a multinational pharmaceutical company such as Jazz Pharma, Merck, Biogen, AbbVie, Pfizer to develop and commercialize its nanoencapsulated cannabinoid products on a worldwide basis.
2. Plan B - In this option, we plan to seek to out-license our products as early as possible in the development cycle, on a regional basis.
3. Plan C - In this option, we plan to do an IPO to continue clinical development and commercialization of pharmaceutical products for anxiety, pain, addiction and other CNS disorders.

Opioid Use Disorder (OUD): The OUD market size was valued at $3.35 billion in 2023 and is projected to grow to $7.48 billion by 2032, exhibiting a CAGR of 9.5%.

Chemotherapy Induced Peripheral Neuropathic Pain (CIPNP): The market size for CIPNP in the seven major markets (US, Germany, Spain, Italy, France, UK and Japan) was around $1.5 billion in 2023.

Anxiety: The global anxiety disorders treatment market size is predicted to increase from $11.5 billion in 2023 growing at a CAGR of 3.6% to approximately $15.9 billion by 2032.

Multiple Sclerosis: The Multiple Sclerosis Drugs market is forecasted to reach $21.52 billion by the year 2024. This projection indicates a steady annual growth rate of 0.98% between 2024 and 2029, leading to a market value of $22.59 billion by 2029.

Epilepsy: The global epilepsy drugs market size was valued at $10.15 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.1% to $15.1 billion in 2030.

• “Aphios Awarded NIH Grant for Combination Therapeutic for Chronic Opioid Use Disorder Relapse” September 06, 2023.
• “Aphios Pharma LLC – Opioid Use Disorder.”
• “Aphios Pharma LLC – Chemotherapy Induced Peripheral Neuropathic Pain (CIPNP).”
• “Aphios Pharma LLC – Anxiety.”
• “Aphios Pharma LLC – Multiple Sclerosis.”
• “Aphios® Pharma LLC to Host Webinar on the Business of Cannabis as a Medicine” July 14, 2022.
• “Aphios Pharma LLC to Host Webinar on the Science and Technology of Cannabis as a Medicine” June 23, 2022.
• “Aphios Pharma LLC to Host Webinar on the Minds, Technology and Science Behind Aphios Pharma” April 21, 2022.
• “Why the US decision to expand marijuana supply for research matters.” Nature. 21 Aug 2016.
• “Cannabis-Based Pharmaceuticals: The Next Frontier?” Life Science Leader. November 2014.

We are a unique scientific and management team with a diversity of backgrounds and experiences in startups to multinationals such as Pfizer and research institutions such as the NIH and MIT.

Our experience ranges from natural products drug discovery and nanotechnology to manufacturing and regulatory and clinical affairs as well as financial and accounting management.

We collaborate with highly qualified clinical trial Contract Research Organizations (CROs) and research institutions such the National Institutes of Health (NIH) and Harvard Medical School, McLean Hospital, Belmont, MA. We operate in a DEA Schedule I facility following cGMP of the US FDA and other federal guidelines.

Join us in our journey to develop natural therapeutics for chronic ailments that affect all of us, our families and friends - pain, anxiety, addiction and debilitating diseases of our central nervous system.

We're all endowed with a natural endocannabinoid system that if unbalanced by internal or external forces can cause or exacerbate these ailments. External cannabinoids can help rebalance our internal endocannabinoid systems. Aphios Pharma can do this with cannabinoids but we have to sustain them in our body longer.

We can do so with our unique and patented nanotechnology platform and get these therapies approved by the FDA with your assistance. We are inspired by nature and enabled by science.